Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. - Wikidata - awgldk - TriplyDB

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

http://www.wikidata.org/entity/Q34368500

about

A comprehensive review on metabolic syndrome Lipid-lowering efficacy of atorvastatin Lipid lowering efficacy of atorvastatin Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?Apolipoprotein[a] secretion from hepatoma cells is regulated in a size-dependent manner by alterations in disulfide bond formation Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A Genetic and environmental pathways to complex diseases.The metabolic syndrome LDL particle size: an important drug target?Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.Lipid disorders in patients with type 2 diabetes. Meeting the challenges of early, aggressive treatment.Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation.Niacin extended-release/lovastatin: combination therapy for lipid disorders.Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4 HPLC-DAD Method for the Pharmacokinetic Interaction Study of Atorvastatin with Pioglitazone and Cholestyramine in Wistar Rats.The effects of different doses of atorvastatin on serum lipid profile, glycemic control, and liver enzymes in patients with ischemic cerebrovascular accident.Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia Pharmacological management of metabolic syndrome and its lipid complications.Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application.Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus Presentation and management of acute hypertriglyceridemic pancreatitis in pregnancy: A case report.A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia The role of statin drugs in the management of the peripheral vascular patient.Early Effects of Treatment Low-Dose Atorvastatin on Markers of Insulin Resistance and Inflammation in Patients with Myocardial Infarction.Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study.Metabolic syndrome: definition and therapeutic implications.Diagnosis and treatment of severe hypertriglyceridemia.Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis.Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?New prospects for lipid-lowering drugs.Post-statin approaches to hyperlipidaemia.Insulin and coronary artery disease: is syndrome X the unifying hypothesis?YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents.Performance evaluation of a novel potentiometric membrane sensor for determination of atorvastatin in pharmaceutical preparations.

P2860

Q21284500-FB4F2FDA-B426-4C9A-B9BA-028E95FB9812 Q24187301-F3017C3A-B1F3-483F-AEA5-E1348C74BA63 Q24202363-7619B05C-5A5C-472F-9A68-3114122D6643 Q24804153-E9F87EF5-AA3A-4499-8C79-A2E9D90667D3 Q28206647-73805C6B-232B-48B6-AE54-D14CE7A164DF Q28571317-DA7DB3E3-C202-47F0-8794-5F8FD138279F Q33439272-0C139154-B0D0-4C83-A788-1C7AB1D3E142 Q33569142-3A0F080C-5513-406F-92C1-AEA7A0F49A9E Q33693960-112D5B67-9837-434C-BF40-601E3D2C0975 Q33938868-C400B2D2-4762-44E6-B7B0-6622FCA582B8 Q34315710-99D23A54-F450-4450-9300-546110DB62A5 Q34373712-05CBF5FA-1D4C-4131-8C2E-89C382CDD510 Q35020544-BD7F12D5-7CC5-4603-8A7A-03F8D5CDB748 Q35045471-76861913-9B59-4D4A-A2F0-6A0FB4D81821 Q35049044-D1526A76-1811-486F-A4F9-41DFD8F9CFB3 Q35052776-94705AB9-013E-46B1-973F-45DD9CD951A4 Q35160603-210C8A25-88AE-461F-BC8E-4007C2D9891C Q35230819-3068D1E2-65F7-4EDF-8F35-B1F4E6110125 Q35580326-826F2B9B-C161-44F0-98F1-62B314BE13F8 Q35832189-FA89FC1C-4976-45C7-AB5B-8001D89755B0 Q36053847-DF577C5A-7B78-4D82-BD24-0CD6BF64449C Q36482113-0FCF9B28-3B53-41FC-AF3C-1B115D883966 Q36954446-52A32EE1-53ED-44F7-95FA-10216454CEF9 Q37070608-DE9B11A6-0C28-4B11-87F5-5E8FE6DFC511 Q37183153-3E6F709F-2CFF-45BB-A09A-2C88211E2F08 Q37214238-2373C426-4B13-4367-AB7B-6991968D0E24 Q37281195-E7FEFE9F-5BE1-4912-B926-823B921A2A57 Q37454427-BF6687C6-39C8-4F65-A26A-D636BFB90570 Q37644907-DC2896B8-EF0E-45C4-BB51-7B1287EE6958 Q37982204-5DCBC474-94CD-4DC5-B55B-D23BE935D765 Q37998115-F2C0F712-D9F6-4868-960C-978EF7BC424F Q38549355-3CD11499-74B5-427B-96BF-ADBFD6E3F299 Q38578940-E8EA2032-82F6-4677-849B-9612DD661D10 Q39456483-530D6A50-9BA2-403B-BF8B-DC77A5F96DF7 Q39528844-E3568158-2CF0-44D8-8DDF-B18D4CA387B1 Q40408992-CCB85AAA-29A7-40DB-A664-F3405C6A034C Q40409025-1E15F065-0280-4B71-A02B-3D390196185D Q41718753-571AA59F-7550-4003-B795-8CA8C6D8F1AA Q41878090-D4EAAAC7-4F91-4762-A88F-4F947756884A Q41937289-6E5766DB-805C-4A0F-A1E8-15485528A4B7

P2860

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

http://www.wikidata.org/entity/Q34368500

description

1996 nî lūn-bûn

@nan

1996 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Efficacy and safety of a new H ...... nts with hypertriglyceridemia.

@ast

Efficacy and safety of a new H ...... nts with hypertriglyceridemia.

@en

Efficacy and safety of a new H ...... nts with hypertriglyceridemia.

@nl

type

label

Efficacy and safety of a new H ...... nts with hypertriglyceridemia.

@ast

Efficacy and safety of a new H ...... nts with hypertriglyceridemia.

@en

Efficacy and safety of a new H ...... nts with hypertriglyceridemia.

@nl

prefLabel

Efficacy and safety of a new H ...... nts with hypertriglyceridemia.

@ast

Efficacy and safety of a new H ...... nts with hypertriglyceridemia.

@en

Efficacy and safety of a new H ...... nts with hypertriglyceridemia.

@nl

P1433

Q34368500-0B5E5974-3B91-4B45-9033-6C50B6258079

P1476

Q34368500-9F54DC50-5C39-4393-902C-9B95204022DD

P2093

Q34368500-091ECFBF-7868-4E72-98EE-FC49A197431C

Q34368500-0C6DA0CC-0538-4EB8-A05F-84DD05073698

Q34368500-25F1B434-19AD-4D2B-B104-D14ABE9C6963

Q34368500-29789BC5-8348-4044-A3E8-F168ED9F481F

Q34368500-345BAAFD-055D-4C8F-8DB7-C086321C0898

Q34368500-441C2C52-8678-492A-BAC3-9FC71003F3D9

Q34368500-49AA6165-70D7-4D67-BE19-6F1B5B867A11

Q34368500-86754821-3359-48A7-83BF-984B8FD69D6E

Q34368500-DEF32C35-F992-469B-BC98-FEF26B8ACC04

Q34368500-E4DFED4B-76D1-4C39-8480-FD68FBE7E2E8

P304

Q34368500-7A9057D4-F365-4547-9E60-ED0E84F55D54

P31

Q34368500-2C211B8F-4E9F-4BB5-97A6-2BAB04BC962D

P356

Q34368500-1A6D515E-1284-4989-B167-C3EE49ACB1F2

P407

Q34368500-8BE78B44-08CC-4113-8888-30145B92C139

P433

Q34368500-39918C12-30BD-4B6C-BB77-6B66AE59560A

P478

Q34368500-57FE2662-8352-4A3D-94AB-9453A0271322

P577

Q34368500-2AEEEEE1-9756-44A3-917B-E17899D83702

P698

Q34368500-C21AE23F-B32B-4669-B6F1-8BE25568597A

P921

Q34368500-A2F7791A-3E34-4747-ACC6-7EA68CBA06BF

P356

JAMA.1996.03530260042029

P1433

Journal of the American Medical Association

P1476

Efficacy and safety of a new H ...... nts with hypertriglyceridemia.

@en

P2093

D M Black

http://www.w3.org/2001/XMLSchema#string

J Davignon

http://www.w3.org/2001/XMLSchema#string

J L Isaacsohn

http://www.w3.org/2001/XMLSchema#string

L J Shurzinske

http://www.w3.org/2001/XMLSchema#string

L M Keilson

http://www.w3.org/2001/XMLSchema#string

M H Davidson

http://www.w3.org/2001/XMLSchema#string

R G Bakker-Arkema

http://www.w3.org/2001/XMLSchema#string

R J Goldstein

http://www.w3.org/2001/XMLSchema#string

S R Weiss

http://www.w3.org/2001/XMLSchema#string

V T Miller

http://www.w3.org/2001/XMLSchema#string

P304

128-133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.1996.03530260042029

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

275

http://www.w3.org/2001/XMLSchema#string

P577

1996-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8531308

http://www.w3.org/2001/XMLSchema#string

P921